BACKGROUND & AIMS: Differential expression of tumor-relevant proteins based on aberrant proteasomal degradation may contribute to human (hepato)carcinogenesis. Recently, we identified the E3 ubiquitin ligase seven in absentia homolog (SIAH)-1 as frequently dysregulated in human hepatocellular carcinoma (HCC). We therefore systematically analyzed the expression, functional relevance, as well as possible downstream effectors of SIAH-1 in human liver carcinogenesis. METHODS: SIAH-1 expression was analyzed at the transcript and protein levels in human hepatocarcinogenesis and in HCC cells. Proliferation, apoptosis, and migration of different HCC cell lines were examined after siRNA-mediated inhibition of SIAH-1. In order to identify downstream effectors that mediate SIAH-1 effects, correlative analyses of protein expression profiles were performed. RESULTS: In HCC tissues both reduction of cytoplasmic SIAH-1 and especially its nuclear accumulation positively correlated with HCC progression. RNA interference revealed that nuclear expression of SIAH-1 predominantly supported HCC cell proliferation and migration while only moderately affecting anti-apoptosis. In de-differentiated human HCCs, nuclear SIAH-1 accumulation significantly correlated with the expression of the transcription factor far-upstream element (FUSE)-binding protein (FBP)-3. In vitro, SIAH-1 positively and indirectly regulated FBP-3 which itself primarily supported HCC cell proliferation. Indeed, high level expression of FBP-3 in human HCCs significantly correlated with reduced overall survival of patients. CONCLUSIONS: Nuclear accumulation of the E3 ubiquitin ligase SIAH-1 supports different pro-tumorigenic cellular processes associated with tumor growth and tumor cell dissemination in human hepatocarcinogenesis. It promotes HCC cell proliferation by at least partly employing the transcription factor FBP-3. Therefore, interference with SIAH-1 activity represents a promising approach to suppress HCC growth.
BACKGROUND & AIMS: Differential expression of tumor-relevant proteins based on aberrant proteasomal degradation may contribute to human (hepato)carcinogenesis. Recently, we identified the E3 ubiquitin ligase seven in absentia homolog (SIAH)-1 as frequently dysregulated in humanhepatocellular carcinoma (HCC). We therefore systematically analyzed the expression, functional relevance, as well as possible downstream effectors of SIAH-1 in human liver carcinogenesis. METHODS:SIAH-1 expression was analyzed at the transcript and protein levels in humanhepatocarcinogenesis and in HCC cells. Proliferation, apoptosis, and migration of different HCC cell lines were examined after siRNA-mediated inhibition of SIAH-1. In order to identify downstream effectors that mediate SIAH-1 effects, correlative analyses of protein expression profiles were performed. RESULTS: In HCC tissues both reduction of cytoplasmic SIAH-1 and especially its nuclear accumulation positively correlated with HCC progression. RNA interference revealed that nuclear expression of SIAH-1 predominantly supported HCC cell proliferation and migration while only moderately affecting anti-apoptosis. In de-differentiated human HCCs, nuclear SIAH-1 accumulation significantly correlated with the expression of the transcription factor far-upstream element (FUSE)-binding protein (FBP)-3. In vitro, SIAH-1 positively and indirectly regulated FBP-3 which itself primarily supported HCC cell proliferation. Indeed, high level expression of FBP-3 in human HCCs significantly correlated with reduced overall survival of patients. CONCLUSIONS: Nuclear accumulation of the E3 ubiquitin ligase SIAH-1 supports different pro-tumorigenic cellular processes associated with tumor growth and tumor cell dissemination in humanhepatocarcinogenesis. It promotes HCC cell proliferation by at least partly employing the transcription factor FBP-3. Therefore, interference with SIAH-1 activity represents a promising approach to suppress HCC growth.
Authors: Jana Samarin; Vibor Laketa; Mona Malz; Stephanie Roessler; Ilan Stein; Elad Horwitz; Stephan Singer; Eleni Dimou; Antonio Cigliano; Michaela Bissinger; Christine Susanne Falk; Xin Chen; Steven Dooley; Eli Pikarsky; Diego Francesco Calvisi; Carsten Schultz; Peter Schirmacher; Kai Breuhahn Journal: Hepatology Date: 2016-01-14 Impact factor: 17.425
Authors: M Gordian Adam; Sonja Matt; Sven Christian; Holger Hess-Stumpp; Andrea Haegebarth; Thomas G Hofmann; Carolyn Algire Journal: Cell Cycle Date: 2015 Impact factor: 4.534
Authors: Paula Moreno; Maribel Lara-Chica; Rafael Soler-Torronteras; Teresa Caro; Manuel Medina; Antonio Álvarez; Ángel Salvatierra; Eduardo Muñoz; Marco A Calzado Journal: PLoS One Date: 2015-11-18 Impact factor: 3.240
Authors: Ali Flores-Pérez; Laurence A Marchat; Sergio Rodríguez-Cuevas; Verónica Piña Bautista; Lizeth Fuentes-Mera; Diana Romero-Zamora; Anabel Maciel-Dominguez; Olga Hernández de la Cruz; Miguel Fonseca-Sánchez; Erika Ruíz-García; Horacio Astudillo-de la Vega; César López-Camarillo Journal: BMC Cancer Date: 2016-07-04 Impact factor: 4.430